会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Compounds and methods for the inhibition of protein-protein interactions
    • 用于抑制蛋白质 - 蛋白质相互作用的化合物和方法
    • US06465192B2
    • 2002-10-15
    • US09208665
    • 1998-12-10
    • Jeffrey C. Way
    • Jeffrey C. Way
    • G01N3353
    • G01N33/6845C40B30/04C40B40/00G01N33/68
    • Compounds having molecular weights of less than 1500 daltons that non-covalently interact with target proteins and covalently bond to target proteins at amino acid side chains that are not part of enzyme active sites, in which covalently bound portions of the compounds sterically block the binding of the target proteins to other proteins, are disclosed. The compounds react with forward reaction rates at least 100 times faster than the forward reaction rates at which the compounds bond to the side chains of the corresponding free amino acids under physiological conditions. Compositions including these compounds and methods for preparing these compounds are also disclosed.
    • 分子量小于1500道尔顿的化合物与靶蛋白非共价相互作用,并且在不属于酶活性位点的氨基酸侧链上与靶蛋白共价键合,其中化合物的共价结合部分空间阻断了 公开了靶蛋白与其他蛋白质。 化合物与正向反应速率反应至少比在生理条件下化合物键合到相应游离氨基酸的侧链的正向反应速率快100倍。 还公开了包括这些化合物的组合物和制备这些化合物的方法。
    • 5. 发明授权
    • Artificial proteins with reduced immunogenicity
    • 具有降低免疫原性的人造蛋白
    • US07615217B2
    • 2009-11-10
    • US11716878
    • 2007-03-12
    • Stephen GilliesFrancis J. CarrJones TimGraham CarterAnita HamiltonStephen WilliamsMarian HanlonJohn WatkinsMatthew BakerJeffrey C. Way
    • Stephen GilliesFrancis J. CarrJones TimGraham CarterAnita HamiltonStephen WilliamsMarian HanlonJohn WatkinsMatthew BakerJeffrey C. Way
    • A61K39/395
    • C07K16/30C07K16/28C07K16/2863C07K2317/24C07K2317/34C07K2319/00C07K2319/30
    • The invention relates to artificial modified proteins, preferably fusion proteins, having a reduced immunogenicity compared to the parent non-modified molecule when exposed to a species in vivo. The invention relates, above all, to novel immunoglobulin fusion proteins which essentially consist of an immunoglobulin molecule or a fragment thereof covalently fused via its C-terminus to the N-terminus of a biologically active non-immunoglobulin molecule, preferably a polypeptide or protein or a biologically active fragment thereof. In a specific embodiment, the invention relates to fusion proteins consisting of an Fc portion of an antibody which is fused as mentioned to the non-immunological target molecule which elicits biological or pharmacological efficacy. The molecules of the invention have amino acid sequences which are altered in one or more amino acid residue positions but have in principal the same biological activity as compared with the non-altered molecules. The changes are made in regions of the molecules which are identified as T-cell epitopes, which contribute to an immune reaction in a living host. Thus, the invention also relates to a novel method of making such fusion proteins by identifying said epitopes comprising calculation of T-cell epitope values for MHC Class II molecule binding sites in a peptide by computer-aided methods.
    • 本发明涉及人体修饰蛋白,优选融合蛋白,当与体内物种暴露时,与亲本非修饰分子相比具有降低的免疫原性。 本发明首先涉及新的免疫球蛋白融合蛋白,其基本上由免疫球蛋白分子或其通过C末端与生物活性非免疫球蛋白分子,优选多肽或蛋白质的N末端共价融合的片段组成,或 其生物活性片段。 在一个具体的实施方案中,本发明涉及由抗体的Fc部分组成的融合蛋白,所述Fc部分如提及的非免疫靶标分子融合而引起生物学或药理学功效。 本发明的分子具有氨基酸序列,其在一个或多个氨基酸残基位置被改变,但与未改变的分子相比具有相同的生物学活性。 在被鉴定为T细胞表位的分子的区域中进行改变,其有助于在宿主中的免疫反应。 因此,本发明还涉及通过鉴定所述表位来制备此类融合蛋白的新方法,包括通过计算机辅助方法计算肽中MHC II类分子结合位点的T细胞表位值。
    • 6. 发明授权
    • Anti-KSA/IL-2 fusion proteins with reduced immunogenicity
    • 抗KSA / IL-2融合蛋白具有降低的免疫原性
    • US07189830B2
    • 2007-03-13
    • US10468370
    • 2002-02-18
    • Stephen GilliesFrancis J. CarrJones TimGraham CarterAnita HamiltonStephen WilliamsMarian HanlonJohn WatkinsMatthew BakerJeffrey C. Way
    • Stephen GilliesFrancis J. CarrJones TimGraham CarterAnita HamiltonStephen WilliamsMarian HanlonJohn WatkinsMatthew BakerJeffrey C. Way
    • C07K14/55C12N15/62
    • C07K16/30C07K16/28C07K16/2863C07K2317/24C07K2317/34C07K2319/00C07K2319/30
    • The invention relates to artificial modified proteins, preferably fusion proteins, having a reduced immunogenicity compared to the parent non-modified molecule when exposed to a species in vivo. The invention relates, above all, to novel immunoglobulin fusion proteins which essentially consist of an immunoglobulin molecule or a fragment thereof covalently fused via its C-terminus to the N-terminus of a biologically active non-immunoglobulin molecule, preferably a polypeptide or protein or a biologically active fragment thereof. In a specific embodiment, the invention relates to fusion proteins consisting of an Fc portion of an antibody which is fused as mentioned to the non-immunological target molecule which elicits biological or pharmacological efficacy. The molecules of the invention have amino acid sequences which are altered in one or more amino acid residue positions but have in principal the same biological activity as compared with the non-altered molecules. The changes are made in regions of the molecules which are identified as T-cell epitopes, which contribute to an immune reaction in a living host. Thus, the invention also relates to a novel method of making such fusion proteins by identifying said epitopes comprising calculation of T-cell epitope values for MHC Class II molecule binding sites in a peptide by computer-aided methods.
    • 本发明涉及人体修饰蛋白,优选融合蛋白,当与体内物种暴露时,与亲本非修饰分子相比具有降低的免疫原性。 本发明首先涉及新的免疫球蛋白融合蛋白,其基本上由免疫球蛋白分子或其通过C末端与生物活性非免疫球蛋白分子,优选多肽或蛋白质的N末端共价融合的片段组成,或 其生物活性片段。 在一个具体的实施方案中,本发明涉及由抗体的Fc部分组成的融合蛋白,所述Fc部分如提及的非免疫靶标分子融合而引起生物学或药理学功效。 本发明的分子具有氨基酸序列,其在一个或多个氨基酸残基位置被改变,但与未改变的分子相比具有相同的生物学活性。 在被鉴定为T细胞表位的分子的区域中进行改变,其有助于在宿主中的免疫反应。 因此,本发明还涉及通过鉴定所述表位来制备此类融合蛋白的新方法,包括通过计算机辅助方法计算肽中MHC II类分子结合位点的T细胞表位值。